Subjective symptoms are triggers for the detection of immune checkpoint inhibitor-induced interstitial lung disease and associate with disease severity: a single-center retrospective study

Subjective symptoms are triggers for the detection of immune checkpoint inhibitor-induced interstitial lung disease and associate with disease severity: a single-center retrospective study

Abstract Background Interstitial lung disease (ILD) is one of the most common fatal immune-related adverse events (irAEs). ILD development adversely affects the continuation of anticancer drug therapy, including immune checkpoint inhibitor (ICI) therapy and prognosis. There are no established useful...

Full description

Bibliographic Details
Main Authors: Mari Yokoi, Atsushi Yonezawa, Daiki Hira, Tomohiro Handa, Kiminobu Tanizawa, Shunsaku Nakagawa, Masahiro Tsuda, Yasuaki Ikemi, Ryo Itotani, Hironori Yoshida, Motoo Nomura, Junichi Matsubara, Kosaku Murakami, Hiroaki Ozasa, Manabu Muto, Tomohiro Terada
Format: Article
Language:English
Published: BMC 2024-08-01
Series:Journal of Pharmaceutical Health Care and Sciences
Subjects:
Immune checkpoint inhibitors
Immune-related adverse events
Drug-induced interstitial lung disease
Subjective symptoms
Online Access:https://doi.org/10.1186/s40780-024-00373-7

Internet

https://doi.org/10.1186/s40780-024-00373-7

Similar Items